| Zhou, JianFeng |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
| Recruiting | 2 | 32 | RoW | Anlotinib, anlotinib hydrochloride, Penpulimab, AK105 | Peking Union Medical College Hospital | Colorectal Cancer | 08/22 | 08/23 | | |
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05320081: Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | CD30 CAR-T, Camrelizumab | Huazhong University of Science and Technology, The First Affiliated Hospital of Nanchang University | Lymphoma, Relapse/Recurrence | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1 | 18 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 01/22 | 03/22 | | |
NCT04767308: Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies |
|
|
| Not yet recruiting | 1 | 18 | NA | CT125A cells, Cyclophosphamide, fludarabine | Huazhong University of Science and Technology, Shanghai IASO Biotechnology Co., Ltd | CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Peripheral T-cell Lymphomas (PTCL) | 09/23 | 12/23 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
NCT03491605: Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection |
|
|
| Recruiting | N/A | 10000 | RoW | peripheral EBV-DNA load | Huazhong University of Science and Technology | EBV Infection | 12/24 | 12/29 | | |
